Please assess the completion status of the following clinical trial:

Trial Title: INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* INCLUSION:~  1. Single-level cervical degenerative disc disease (from C3-C7) requiring surgical treatment and involving intractable radiculopathy and/or myelopathy.~ 2. Herniated disc and/or osteophyte formation at the level to be treated that is producing symptomatic nerve root and/or spinal cord compression.~ 3. Unresponsive to non-operative treatment for six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management.~ 4. At least 18 years of age and skeletally mature at the time of surgery.~ 5. A preoperative Neck Disability Index (NDI) score ≥30.~ 6. A preoperative neck pain score (pain intensity + pain frequency) ≥8 (out of 20) based on the preoperative Neck and Arm Pain Questionnaire.~ 7. If a female of childbearing potential, patient is not pregnant or nursing and agrees not to become pregnant for one year following surgery.~ 8. Is willing and able to comply with the study plan and able to understand and sign the Patient Informed Consent Form.~Exclusion Criteria:~* EXCLUSION:~  1. A cervical spinal condition other than symptomatic cervical degenerative disc disease requiring surgical treatment at the involved level.~ 2. Documented or diagnosed cervical instability at the target level, defined by dynamic (flexion/extension) radiographs.~ 3. Previous surgical intervention at the involved level.~ 4. Any subsequent planned/staged surgical procedure at the involved or adjacent level(s).~ 5. Fused level adjacent to the level to be treated.~ 6. Severe pathology of the facet joints of the involved vertebral bodies.~ 7. Has osteoporosis, osteopenia, or osteomalacia as determined by DEXA scan.~ 8. Presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).~ 9. Overt or active bacterial infection, either local or systemic.~ 10. Insulin dependent diabetes.~ 11. Chronic or acute renal failure or prior history of renal disease.~ 12. Documented allergy or intolerance to stainless steel, titanium, titanium alloy, polyetheretherketone (PEEK), or tantalum.~ 13. Is mentally incompetent. (if questionable, obtain psychiatric consult.)~ 14. Is a prisoner.~ 15. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse.~ 16. On oral or injectable steroids for 6 weeks or more at the time of enrollment.~ 17. A history of autoimmune disease.~ 18. History of exposure to injectable collagen or silicone implants.~ 19. History of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.~ 20. Received any previous exposure to any/all BMPs either human or animal extraction.~ 21. History of allergy to bovine products.~ 22. History of any allergy resulting in anaphylaxis.~ 23. History of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta).~ 24. Condition that requires postoperative medications that interfere with the stability of the implant, such as steroids.~ 25. Received treatment with an investigational therapy (drug, device, or biologic) within 28 days prior to implantation surgery or such treatment is planned during the 24-month period following the study surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INFUSE® Bone Graft (Type: EXPERIMENTAL): In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.

Based on this trial design, predict the completion outcome and termination type (if applicable).